data/medical_terms_cache.json

{
  "synonyms": {
    "european society of medical oncology": [
      "esmo"
    ],
    "esmo": [
      "european society for medical oncology",
      "european society of medical oncology",
      "european\nsociety of medical oncology",
      "the european society for medical oncology",
      "the european society for medical\noncology",
      "european society for\nmedical oncology"
    ],
    "american society of clinical\n\noncology": [
      "asco"
    ],
    "asco": [
      "american society of clinical oncology",
      "inc",
      "american\nsociety of clinical oncology",
      "american society of clinical\n\noncology",
      "s note\n\nthis american society of clinical oncology",
      "md american society of clinical oncology",
      "journal of clinical oncology"
    ],
    "italian association of medical oncology": [
      "aiom"
    ],
    "aiom": [
      "italian association\nof medical oncology",
      "italian association of medical oncology"
    ],
    "national comprehensive cancer network": [
      "nccn"
    ],
    "nccn": [
      "national comprehensive cancer network",
      "vs insurance-based",
      "leading american cancer centers"
    ],
    "non-small cell lung cancer": [
      "nsclc"
    ],
    "nsclc": [
      "advanced non-small-cell lung cancer",
      "-rearranged advanced non-small-cell lung cancer",
      "small-cell lung cancer",
      "advanced non-small cell lung cancer",
      "small cell\nlung cancer",
      "non-small-cell lung cancer",
      "iii non-small-cell lung cancer",
      "small cell lung cancer",
      "stage iii non small cell lung cancer",
      "small-cell\nlung cancer",
      "e-mutant advanced non-small cell lung cancer",
      "non-small cell lung cancer",
      "cancer",
      "robotic lobectomy for non-small cell lung cancer",
      "mutant advanced non-small cell lung cancer",
      "lung cancer"
    ],
    "american\nsociety of clinical oncology": [
      "asco"
    ],
    "italian association\nof medical oncology": [
      "aiom"
    ],
    "european\nsociety of medical oncology": [
      "esmo"
    ],
    "leading american cancer centers": [
      "nccn"
    ],
    "using the guidelines into decision\nsupport": [
      "glides"
    ],
    "glides": [
      "guidelines into decision support",
      "using the guidelines into decision support",
      "using the guidelines into decision\nsupport"
    ],
    "for all the newly\neuropean medicines agency": [
      "ema"
    ],
    "ema": [
      "not european medicines agency",
      "and the european medicines\nagency",
      "for all the newly european medicines agency",
      "and the european medicines agency",
      "european medicines agency",
      "for all the newly\neuropean medicines agency"
    ],
    "evaluates treatments with curative intent": [
      "such\nas adjuvant chemotherapy",
      "such as adjuvant chemotherapy"
    ],
    "such\nas adjuvant chemotherapy": [
      "evaluates treatments with curative intent"
    ],
    "panel members": [
      "from\ndifferent institutions",
      "from different institutions"
    ],
    "from\ndifferent institutions": [
      "panel members"
    ],
    "and the\nearly study interruption": [
      "even if based on pre-specified\ninterim analysis"
    ],
    "even if based on pre-specified\ninterim analysis": [
      "and the\nearly study interruption"
    ],
    "-positive nonsmall-cell lung cancer": [
      "magrit"
    ],
    "magrit": [
      "-positive nonsmall-cell lung cancer",
      "-positive non-small-cell lung cancer"
    ],
    "guidelines into decision support": [
      "glides"
    ],
    "early-stage and\n\nlocally advanced": [
      "non-metastatic"
    ],
    "non-metastatic": [
      "early-stage and locally advanced",
      "early-stage and\n\nlocally advanced"
    ],
    "or best supportive\ncare": [
      "bsc"
    ],
    "bsc": [
      "or best supportive\ncare",
      "leads to increased dfs versus best supportive care",
      "or best supportive care",
      "leads to\nincreased dfs versus best supportive care"
    ],
    "author affiliations\nand support\n\ninformation": [
      "if\n\napplicable"
    ],
    "if\n\napplicable": [
      "author affiliations\nand support\n\ninformation"
    ],
    "small-cell lung cancers": [
      "nsclcs"
    ],
    "nsclcs": [
      "small-cell lung cancers"
    ],
    "two randomized control trials": [
      "rcts"
    ],
    "rcts": [
      "controlled trials",
      "two randomized control trials",
      "clinical trials"
    ],
    "the primary end point was disease-free\nsurvival": [
      "dfs"
    ],
    "dfs": [
      "disease-free survival",
      "the primary end point was disease-free\nsurvival",
      "the primary end point was disease-free survival"
    ],
    "joint cancer care ontario": [
      "cco"
    ],
    "cco": [
      "joint cancer care ontario"
    ],
    "small-cell\nlung cancer": [
      "nsclc"
    ],
    "puma biotechnology": [
      "inst"
    ],
    "inst": [
      "exelixis",
      "astex pharmaceuticals",
      "boehringer ingelheim",
      "regeneron",
      "crispr therapeutics",
      "cullinan oncology",
      "guardant health",
      "arcus biosciences",
      "palobiofarma",
      "sutro biopharma",
      "merck serono",
      "verastem",
      "anheart therapeutics",
      "elevation oncology",
      "bristol myers squibb foundation",
      "calithera biosciences",
      "takeda",
      "black diamond therapeutics",
      "novartis",
      "bayer",
      "bristol myers squibb",
      "constellation pharmaceuticals",
      "oncomed",
      "jazz pharmaceuticals",
      "msd",
      "glaxosmithkline canada",
      "blueprint medicines",
      "therapeutics",
      "roche",
      "neogenomics",
      "turning point therapeutics",
      "janssen oncology",
      "lilly",
      "black diamond\ntherapeutics",
      "abbvie",
      "astra zeneca",
      "harpoon therapeutics",
      "inhibrx",
      "gsk",
      "pfizer",
      "revolution medicines",
      "advaxis",
      "dizal pharma",
      "merck",
      "janssen",
      "oric pharmaceuticals",
      "macrogenics",
      "summit therapeutics",
      "genentech",
      "bristol myers\nsquibb",
      "glaxosmithkline",
      "bms",
      "amgen",
      "puma biotechnology",
      "vivace therapeutics",
      "nuvation bio",
      "pharmamar",
      "astrazeneca canada",
      "medimmune",
      "forward",
      "astrazeneca",
      "polaris",
      "inc",
      "bristol-myers squibb",
      "trizell",
      "dizal\npharma",
      "mirati therapeutics",
      "dohme",
      "crispr\ntherapeutics"
    ],
    "pfizer": [
      "inst"
    ],
    "genentech": [
      "inst"
    ],
    "bristol-myers squibb": [
      "inst",
      "bms"
    ],
    "medimmune": [
      "inst"
    ],
    "of patients with\nstage i to iii sclc": [
      "limited stage"
    ],
    "limited stage": [
      "of patients with\nstage i to iii sclc",
      "of patients with stage i to iii sclc"
    ],
    "small-cell lung cancer": [
      "nsclc",
      "pacific"
    ],
    "or small-cell lung cancer": [
      "sclc"
    ],
    "sclc": [
      "small cell lung cancer",
      "and small-cell lung cancer",
      "trial in small cell lung cancer",
      "or small-cell lung cancer"
    ],
    "cancer": [
      "relay",
      "nsclc"
    ],
    "and small-cell lung cancer": [
      "sclc"
    ],
    "with contrast": [
      "preferred"
    ],
    "preferred": [
      "with contrast"
    ],
    "prophylactic cranial irradiation": [
      "pci"
    ],
    "pci": [
      "prophylactic cranial irradiation",
      "dose prophylactic cranial irradiation"
    ],
    "the bottom line": [
      "continued"
    ],
    "continued": [
      "medical guideline document - esmo open references",
      "all recommendations",
      "the bottom line"
    ],
    "salvage stereotactic body radiation therapy": [
      "sbrt"
    ],
    "sbrt": [
      "stereotactic body radiotherapy",
      "salvage stereotactic body radiation therapy",
      "sabr or stereotactic body radiotherapy",
      "fdg-pet and stereotactic body radiotherapy"
    ],
    "oncomed": [
      "inst"
    ],
    "macrogenics": [
      "inst"
    ],
    "astrazeneca": [
      "inst"
    ],
    "thecollege of americanpathologists": [
      "cap"
    ],
    "cap": [
      "thecollege of americanpathologists",
      "the college of american pathologists"
    ],
    "association\nfor molecular pathology": [
      "amp"
    ],
    "amp": [
      "association for molecular pathology",
      "association\nfor molecular pathology"
    ],
    "and anaplastic lymphoma kinase": [
      "alk"
    ],
    "alk": [
      "phoma kinase",
      "and anaplastic lymphoma kinase",
      "positive anaplastic lymphoma kinase",
      "crizotinib-pretreated anaplastic lymphoma kinase"
    ],
    "immunohistochemistry": [
      "ihc"
    ],
    "ihc": [
      "egfr fish or immunohistochemistry",
      "immunohistochemistry"
    ],
    "merck": [
      "german",
      "inst"
    ],
    "glaxosmithkline": [
      "gsk",
      "inst"
    ],
    "astex pharmaceuticals": [
      "inst"
    ],
    "takeda": [
      "inst"
    ],
    "bristol myers\nsquibb": [
      "inst",
      "bms"
    ],
    "polaris": [
      "inst"
    ],
    "inhibrx": [
      "inst"
    ],
    "vivace therapeutics": [
      "inst"
    ],
    "constellation pharmaceuticals": [
      "inst"
    ],
    "harpoon therapeutics": [
      "inst"
    ],
    "bayer": [
      "inst"
    ],
    "novartis": [
      "inst"
    ],
    "crispr\ntherapeutics": [
      "inst"
    ],
    "calithera biosciences": [
      "inst"
    ],
    "therapeutics": [
      "inst"
    ],
    "stage iii non small cell lung cancer": [
      "nsclc"
    ],
    "immune checkpoint inhibitors": [
      "icis"
    ],
    "icis": [
      "immune checkpoint inhibitors",
      "neoadjuvant immune checkpoint inhibitors"
    ],
    "american society of clinical oncology": [
      "asco"
    ],
    "boehringer ingelheim": [
      "inst"
    ],
    "pharmamar": [
      "inst"
    ],
    "roche": [
      "inst"
    ],
    "janssen": [
      "inst"
    ],
    "merck serono": [
      "inst"
    ],
    "bms": [
      "bristol\nmyers squibb",
      "bristol myers\nsquibb",
      "bristol-myers\nsquibb",
      "bristol-myers squibb",
      "celgene",
      "inst",
      "bristol myers squibb"
    ],
    "trizell": [
      "inst"
    ],
    "amgen": [
      "inst"
    ],
    "clinical lung cancer": [
      "elsevier"
    ],
    "elsevier": [
      "clinical lung cancer"
    ],
    "one randomized controlled trial": [
      "rct"
    ],
    "rct": [
      "one randomized controlled trial",
      "phase iib\nrandomised controlled trial",
      "phase iii randomised clinical trial",
      "phase iib randomised controlled trial",
      "a phase iii randomised clinical trial"
    ],
    "the primary end point of progression-free survival": [
      "pfs"
    ],
    "pfs": [
      "quality of life and progression-free survival",
      "the primary end point of progression-free survival",
      "and\nprogression-free survival",
      "the median progression-free\nsurvival",
      "no\nimprovement in progression-free survival",
      "reported improved\nprogression-free survival",
      "the median progression-free survival",
      "and progression-free survival",
      "progression-free survival",
      "the median\nprogression-free survival",
      "reported improved progression-free survival"
    ],
    "adverse events": [
      "all-cause",
      "aes"
    ],
    "aes": [
      "mainly altered lipid levels",
      "adverse events",
      "adverse\nevents"
    ],
    "and consolidation": [
      "for unresectable stage iii nsclc"
    ],
    "for unresectable stage iii nsclc": [
      "and consolidation"
    ],
    "treatment is now an\negfr-targeted drug": [
      "osimertinib"
    ],
    "osimertinib": [
      "osi",
      "treatment is now an\negfr-targeted drug",
      "treatment is now an egfr-targeted drug"
    ],
    "inc": [
      "inst",
      "asco"
    ],
    "small cell\nlung cancer": [
      "nsclc"
    ],
    "the median\nprogression-free survival": [
      "pfs"
    ],
    "adverse\nevents": [
      "aes"
    ],
    "and vascular\nendothelial growth factor": [
      "vegf"
    ],
    "vegf": [
      "and vascular\nendothelial growth factor",
      "and vascular endothelial growth factor"
    ],
    "though rates of\nimmune-related aes": [
      "iraes"
    ],
    "iraes": [
      "though rates of immune-related aes",
      "though rates of\nimmune-related aes"
    ],
    "bristol myers squibb": [
      "inst",
      "bms"
    ],
    "palobiofarma": [
      "inst"
    ],
    "dohme": [
      "msd",
      "inst"
    ],
    "mirati therapeutics": [
      "inst"
    ],
    "abbvie": [
      "inst"
    ],
    "blueprint medicines": [
      "inst"
    ],
    "advaxis": [
      "inst"
    ],
    "janssen oncology": [
      "inst"
    ],
    "elevation oncology": [
      "inst"
    ],
    "black diamond\ntherapeutics": [
      "inst"
    ],
    "forward": [
      "inst"
    ],
    "gsk": [
      "glaxosmithkline",
      "inst"
    ],
    "regeneron": [
      "inst"
    ],
    "jazz pharmaceuticals": [
      "inst"
    ],
    "oric pharmaceuticals": [
      "inst"
    ],
    "summit therapeutics": [
      "inst"
    ],
    "turning point therapeutics": [
      "inst"
    ],
    "anheart therapeutics": [
      "inst"
    ],
    "nuvation bio": [
      "inst"
    ],
    "and terminology": [
      "data supplement"
    ],
    "data supplement": [
      "and terminology"
    ],
    "nab-paclitaxel with or without bevacizumab": [
      "in the absence of\ncontraindications to bevacizumab",
      "in the absence of contraindications to bevacizumab"
    ],
    "in the absence of\ncontraindications to bevacizumab": [
      "nab-paclitaxel with or without bevacizumab"
    ],
    "paclitaxel": [
      "or nab-paclitaxel"
    ],
    "or nab-paclitaxel": [
      "paclitaxel"
    ],
    "all recommendations": [
      "continued"
    ],
    "interdisciplinary palliative care teams": [
      "consultation"
    ],
    "consultation": [
      "interdisciplinary palliative care teams"
    ],
    "md american society of clinical oncology": [
      "asco"
    ],
    "va asco practice guideline staff": [
      "health research methods"
    ],
    "health research methods": [
      "asco practice guidelines staff",
      "va asco practice guidelines staff",
      "asco practice guideline staff",
      "va asco practice guideline staff"
    ],
    "in tyrosine kinase inhibitor": [
      "tki"
    ],
    "tki": [
      "in tyrosine kinase inhibitor",
      "tyrosine kinase inhibitor"
    ],
    "reuss et al\n\n\n\nrate": [
      "orr"
    ],
    "orr": [
      "rate",
      "reuss et al\n\n\n\nrate",
      "which had an overall response rate",
      "- objective response rate"
    ],
    "disease control rate": [
      "dcr"
    ],
    "dcr": [
      "disease control rate"
    ],
    "limited generalizability": [
      "united states only"
    ],
    "united states only": [
      "limited generalizability"
    ],
    "with a median duration of\nresponse": [
      "dor"
    ],
    "dor": [
      "the median duration of response",
      "the median\nduration of response",
      "with a median duration of\nresponse",
      "- duration of response",
      "with a median duration of response"
    ],
    "the most common treatment-emergent adverse events": [
      "teaes"
    ],
    "teaes": [
      "the most common treatment-emergent adverse events"
    ],
    "verastem": [
      "inst"
    ],
    "exelixis": [
      "inst"
    ],
    "arcus biosciences": [
      "inst"
    ],
    "revolution medicines": [
      "inst"
    ],
    "sutro biopharma": [
      "inst"
    ],
    "dizal\npharma": [
      "inst"
    ],
    "msd": [
      "dohme",
      "inst"
    ],
    "lilly": [
      "inst"
    ],
    "astrazeneca canada": [
      "inst"
    ],
    "neogenomics": [
      "inst"
    ],
    "guardant health": [
      "inst"
    ],
    "glaxosmithkline canada": [
      "inst"
    ],
    "va asco practice guidelines staff": [
      "health research methods"
    ],
    "was published by asco and ontario health": [
      "cancer care ontario"
    ],
    "cancer care ontario": [
      "was published by asco and ontario health",
      "asco-ontario health"
    ],
    "the median progression-free\nsurvival": [
      "pfs"
    ],
    "pneumonitis": [
      "of any cause"
    ],
    "of any cause": [
      "pneumonitis"
    ],
    "consolidation immunotherapy": [
      "durvalumab"
    ],
    "durvalumab": [
      "if ps improves\n\nv\n\nconsolidation immunotherapy",
      "if ps improves\n- consolidation immunotherapy",
      "consolidation immunotherapy"
    ],
    "if ps improves\n\nv\n\nconsolidation immunotherapy": [
      "durvalumab"
    ],
    "and sclc-i": [
      "inflamed phenotype"
    ],
    "inflamed phenotype": [
      "and sclc-i"
    ],
    "a bispecific t-cell\nengager": [
      "bite"
    ],
    "bite": [
      "a bispecific t-cell engager",
      "a bispecific t-cell\nengager"
    ],
    "the most\ncommon ae was cytokine release syndrome": [
      "crs"
    ],
    "crs": [
      "the most common ae was cytokine release syndrome",
      "cytokine release syndrome",
      "the most\ncommon ae was cytokine release syndrome"
    ],
    "asco-ontario health": [
      "cancer care ontario"
    ],
    "trial in small cell lung cancer": [
      "sclc"
    ],
    "cullinan oncology": [
      "inst"
    ],
    "astra zeneca": [
      "inst"
    ],
    "bristol myers squibb foundation": [
      "inst"
    ],
    "and\nprogression-free survival": [
      "pfs"
    ],
    "the us food and drug administration": [
      "fda"
    ],
    "fda": [
      "the food and drug administration",
      "the us food and drug administration",
      "or food and drug administration",
      "food and drug administration",
      "and the united states food and drug administration",
      "entrectinib received food and drug administration",
      "entrectinib received food and\ndrug administration",
      "and the food and drug administration"
    ],
    "cytokine release syndrome": [
      "crs"
    ],
    "associated neurotoxicity\nsyndrome": [
      "icans"
    ],
    "icans": [
      "associated neurotoxicity\nsyndrome",
      "associated neurotoxicity syndrome"
    ],
    "department of surgical sciences": [
      "ikv"
    ],
    "ikv": [
      "department of surgical sciences"
    ],
    "has grouped lung and thymic neuroendocrine\ntumours": [
      "nets"
    ],
    "nets": [
      "has grouped lung and thymic neuroendocrine\ntumours",
      "has grouped lung and thymic neuroendocrine tumours",
      "tumors"
    ],
    "small cell lung cancer": [
      "nsclc",
      "sclc"
    ],
    "and\nlarge cell neuroendocrine carcinoma": [
      "lcnec"
    ],
    "lcnec": [
      "and large cell neuroendocrine carcinoma",
      "and\nlarge cell neuroendocrine carcinoma"
    ],
    "and thymic\ncarcinoid": [
      "thc"
    ],
    "thc": [
      "and thymic\ncarcinoid",
      "and thymic carcinoid"
    ],
    "org": [
      "esmo guidelines committee"
    ],
    "esmo guidelines committee": [
      "org"
    ],
    "epidemiology and end results": [
      "seer"
    ],
    "seer": [
      "and end results",
      "epidemiology and end results"
    ],
    "s syndrome": [
      "cus"
    ],
    "cus": [
      "s syndrome"
    ],
    "due to adrenocorticotropic hormone": [
      "acth"
    ],
    "acth": [
      "due to adrenocorticotropic hormone"
    ],
    "due to\ngrowth hormone-releasing hormone": [
      "ghrh"
    ],
    "ghrh": [
      "due to\ngrowth hormone-releasing hormone",
      "due to growth hormone-releasing hormone"
    ],
    "contrast": [
      "liver mri"
    ],
    "liver mri": [
      "contrast"
    ],
    "mediastinoscopy": [
      "or ebus"
    ],
    "or ebus": [
      "mediastinoscopy"
    ],
    "contrast-enhanced cross-sectional conventional": [
      "radiological"
    ],
    "radiological": [
      "contrast-enhanced cross-sectional conventional"
    ],
    "-labelled somatostatin analogues": [
      "ssas"
    ],
    "ssas": [
      "medical options",
      "what is the role of somatostatin analogues",
      "-labelled somatostatin analogues"
    ],
    "urinary-free cortisol": [
      "ufc"
    ],
    "ufc": [
      "urinary-free cortisol"
    ],
    "neuroendocrine tumor test": [
      "netest"
    ],
    "netest": [
      "neuroendocrine tumor test"
    ],
    "the who classification and pathological tnm": [
      "ptnm"
    ],
    "ptnm": [
      "the who classification and pathological tnm"
    ],
    "tumour burden and somatostatin receptor imaging": [
      "sri"
    ],
    "sri": [
      "tumour burden and somatostatin receptor imaging"
    ],
    "surgery\nrepresents the treatment of choice for lcs": [
      "both tcs and\nacs"
    ],
    "both tcs and\nacs": [
      "surgery\nrepresents the treatment of choice for lcs"
    ],
    "medical options": [
      "ssas"
    ],
    "a combined approach": [
      "sternotomy plus anterior thoracotomy"
    ],
    "sternotomy plus anterior thoracotomy": [
      "a combined approach"
    ],
    "mainly cytotoxic chemotherapy": [
      "cht"
    ],
    "cht": [
      "platinum-based chemo\ntherapy",
      "mainly cytotoxic chemotherapy",
      "platinum-based chemotherapy",
      "the addition of the chemotherapy",
      "over platinum-based doublet chemotherapy",
      "over platinum-based doublet\nchemotherapy",
      "with or without prior adjuvant chemotherapy",
      "chemotherapy",
      "the beneficial effects of adjuvant chemotherapy"
    ],
    "or systemic therapies": [
      "with options discussed in these guidelines",
      "with options\ndiscussed in these guidelines"
    ],
    "with options\ndiscussed in these guidelines": [
      "or systemic therapies"
    ],
    "in case of\nclinical": [
      "functioning syndrome"
    ],
    "functioning syndrome": [
      "in case of\nclinical",
      "in case of clinical"
    ],
    "and the united states food and drug administration": [
      "fda"
    ],
    "annals of oncology\n\n\n\nparathyroid hormone": [
      "pth"
    ],
    "pth": [
      "parathyroid hormone",
      "annals of oncology\n\n\n\nparathyroid hormone"
    ],
    "palliative surgery\nor radiofrequency ablation": [
      "rfa"
    ],
    "rfa": [
      "palliative surgery or radiofrequency ablation",
      "palliative surgery\nor radiofrequency ablation",
      "for these patients radiofrequency ablation"
    ],
    "or cryoablation or endobronchial treatment": [
      "ebt"
    ],
    "ebt": [
      "or cryoablation or endobronchial treatment"
    ],
    "peptide\nreceptor radionuclide therapy": [
      "prrt"
    ],
    "prrt": [
      "peptide receptor radionuclide therapy",
      "peptide\nreceptor radionuclide therapy"
    ],
    "and interferon- a": [
      "ifna"
    ],
    "ifna": [
      "and interferon- a"
    ],
    "long-acting release": [
      "lar"
    ],
    "lar": [
      "long-acting release"
    ],
    "progression-free rate": [
      "pfr"
    ],
    "pfr": [
      "progression-free rate"
    ],
    "progression before enrolment": [
      "luna study"
    ],
    "luna study": [
      "progression before enrolment"
    ],
    "placebo-controlled trial": [
      "sanet"
    ],
    "sanet": [
      "placebo-controlled trial"
    ],
    "oxaliplatin combined with gemcitabine": [
      "gemox"
    ],
    "gemox": [
      "oxaliplatin combined with gemcitabine"
    ],
    "or capecitabine": [
      "capox"
    ],
    "capox": [
      "or capecitabine"
    ],
    "-fluorouracil": [
      "folfox"
    ],
    "folfox": [
      "uorouracil",
      "-fluorouracil"
    ],
    "as alternative second-line": [
      "in case of uncontrolled cs",
      "in case of\nuncontrolled cs"
    ],
    "in case of\nuncontrolled cs": [
      "as alternative second-line"
    ],
    "or mainly third-line therapy": [
      "beyond\nssas and or everolimus",
      "beyond ssas and or everolimus"
    ],
    "beyond\nssas and or everolimus": [
      "or mainly third-line therapy"
    ],
    "ifn- a as a potential second-line": [
      "in case of uncontrolled\ncs"
    ],
    "in case of uncontrolled\ncs": [
      "ifn- a as a potential second-line"
    ],
    "or mainly third-line alternative": [
      "beyond ssas and or everolimus",
      "beyond ssas and or\neverolimus"
    ],
    "beyond ssas and or\neverolimus": [
      "or mainly third-line alternative"
    ],
    "thymic net recurrences may be local": [
      "if located in the anterior mediastinum",
      "if located in the\nanterior mediastinum"
    ],
    "if located in the\nanterior mediastinum": [
      "thymic net recurrences may be local"
    ],
    "regional": [
      "intrathoracic especially\npleural",
      "intrathoracic especially pleural"
    ],
    "intrathoracic especially\npleural": [
      "regional"
    ],
    "an esmo\nmagnitude of clinical benefit scale": [
      "esmo-mcbs"
    ],
    "esmo-mcbs": [
      "esmo-magnitude of clinical benefit scale",
      "esmo-magnitude of clinical benefit",
      "esmo-magnitude of\nclinical benefit",
      "esmomagnitude of clinical benefit scale",
      "an esmo magnitude of clinical benefit scale",
      "an esmo\nmagnitude of clinical benefit scale",
      "esmo-magnitude of clinical\nbenefit"
    ],
    "advanced carcinoids of the lung and thymus": [
      "luna"
    ],
    "luna": [
      "advanced carcinoids of the lung and thymus"
    ],
    "neuroendocrine cell hyperplasia": [
      "dipnech"
    ],
    "dipnech": [
      "neuroendocrine cell hyperplasia"
    ],
    "neuroendocrine carcinomas": [
      "carcinoid tumor"
    ],
    "carcinoid tumor": [
      "neuroendocrine carcinomas"
    ],
    "and end results": [
      "seer"
    ],
    "synchronous multiple neuroendocrine lung tumours": [
      "case series"
    ],
    "case series": [
      "synchronous multiple neuroendocrine lung tumours"
    ],
    "tumors": [
      "nets"
    ],
    "mo lanreotide autogel": [
      "lan"
    ],
    "lan": [
      "mo lanreotide autogel"
    ],
    "and temozolomide": [
      "tmz"
    ],
    "tmz": [
      "and temozolomide"
    ],
    "neuroendocrine tumours": [
      "tnets"
    ],
    "tnets": [
      "neuroendocrine tumours"
    ],
    "centre hospitalier universitaire vaudois": [
      "chuv"
    ],
    "chuv": [
      "centre hospitalier universitaire\nvaudois",
      "centre hospitalier universitaire vaudois"
    ],
    "comparing low-dose computed tomography": [
      "ldct"
    ],
    "ldct": [
      "low-dose ct",
      "comparing low-dose computed tomography"
    ],
    "such as lepidic adenocarcinomas": [
      "previously named bronchioloalveolar carcinoma"
    ],
    "previously named bronchioloalveolar carcinoma": [
      "such as lepidic adenocarcinomas"
    ],
    "how to handle": [
      "false-"
    ],
    "false-": [
      "how to handle"
    ],
    "or endoscopic\nultrasound": [
      "eus"
    ],
    "eus": [
      "or endoscopic\nultrasound",
      "or endoscopic ultrasound"
    ],
    "the recent world health organization": [
      "who"
    ],
    "who": [
      "world health organization",
      "the recent world health organization",
      "vs universal",
      "global",
      "global statistics"
    ],
    "with its further sub-classification of": [
      "surgically resected"
    ],
    "surgically resected": [
      "with its further sub-classification of"
    ],
    "the beneficial effects of adjuvant chemotherapy": [
      "cht"
    ],
    "the categories adenocarcinoma in situ": [
      "ais"
    ],
    "ais": [
      "the categories adenocarcinoma in situ",
      "proposed that ais be classified as tis",
      "proposed\nthat ais be classified as tis"
    ],
    "minimally invasive adenocarcinoma": [
      "mia"
    ],
    "mia": [
      "minimally invasive adenocarcinoma"
    ],
    "and lepidic predominant": [
      "lep"
    ],
    "lep": [
      "and lepidic predominant"
    ],
    "of fluorodeoxyglucose-positron emission tomography": [
      "fdg-pet"
    ],
    "fdg-pet": [
      "of fluorodeoxyglucose-positron emission tomography"
    ],
    "the rate of nos": [
      "not otherwise\nspecified",
      "not otherwise specified"
    ],
    "not otherwise\nspecified": [
      "the rate of nos"
    ],
    "the union for\ninternational cancer control": [
      "uicc"
    ],
    "uicc": [
      "union for international\ncancer control",
      "the union for\ninternational cancer control",
      "the union for international cancer control",
      "union for international cancer control"
    ],
    "node and metastasis": [
      "tnm"
    ],
    "tnm": [
      "node and metastasis",
      "tumourenodeemetastasis",
      "tumour-node-metastasis"
    ],
    "proposed\nthat ais be classified as tis": [
      "ais"
    ],
    "the display is best with wide": [
      "lung"
    ],
    "lung": [
      "the display is best with wide"
    ],
    "a should be restricted to the same histological": [
      "sub"
    ],
    "sub": [
      "research support as",
      "a should be restricted to the same histological"
    ],
    "videoassisted mediastinoscopy": [
      "vam"
    ],
    "vam": [
      "videoassisted mediastinoscopy"
    ],
    "whereas the american college of chest physicians": [
      "accp"
    ],
    "accp": [
      "the\namerican college of chest physicians",
      "whereas the american college of chest physicians",
      "the american college of chest physicians"
    ],
    "adjuvant chemotherapy": [
      "radiotherapy"
    ],
    "radiotherapy": [
      "adjuvant chemotherapy"
    ],
    "or a video-assisted thoracoscopic surgery": [
      "vats"
    ],
    "vats": [
      "or a video-assisted thoracoscopic surgery",
      "video-assisted thoracic surgery"
    ],
    "based on the lung cancer study group": [
      "lcsg"
    ],
    "lcsg": [
      "based on the lung cancer study group"
    ],
    "research based on large databases suggest a": [
      "limited"
    ],
    "limited": [
      "research based on large databases suggest a"
    ],
    "acc guidelines\n\nneed for coronary\nintervention": [
      "cabg or pci"
    ],
    "cabg or pci": [
      "including",
      "acc guidelines\n\nneed for coronary\nintervention"
    ],
    "high risk surgery": [
      "including\nlobectomy or pneumonectomy"
    ],
    "including\nlobectomy or pneumonectomy": [
      "high risk surgery"
    ],
    "disease": [
      "stage ii and\niii"
    ],
    "stage ii and\niii": [
      "disease"
    ],
    "sabr or stereotactic body radiotherapy": [
      "sbrt"
    ],
    "in those with proven recurrence": [
      "or a high suspicion"
    ],
    "or a high suspicion": [
      "in those with proven recurrence"
    ],
    "for these patients radiofrequency ablation": [
      "rfa"
    ],
    "clinical trials": [
      "rcts"
    ],
    "the induction regimen of chemoradiotherapy": [
      "crt"
    ],
    "crt": [
      "the induction regimen of chemoradiotherapy"
    ],
    "sequential crt": [
      "induction cht followed by rt"
    ],
    "induction cht followed by rt": [
      "sequential crt"
    ],
    "- immunotherapy is being studied in early nsclc as": [
      "neo"
    ],
    "neo": [
      "the\nimmune strategy in the",
      "- immunotherapy is being studied in early nsclc as",
      "resection and after",
      "the immune strategy in the",
      "immunotherapy is being studied in early nsclc as"
    ],
    "cl\n\ntreatment of locally advanced stage": [
      "stage ill"
    ],
    "stage ill": [
      "cl\n\ntreatment of locally advanced stage"
    ],
    "immunotherapy is being studied in early nsclc as": [
      "neo"
    ],
    "controlled trial of good methodological quality": [
      "low potential for bias"
    ],
    "low potential for bias": [
      "controlled trial of good methodological quality"
    ],
    "or imaging": [
      "preferably ct"
    ],
    "preferably ct": [
      "or imaging"
    ],
    "european society of gastrointestinal endoscopy": [
      "esge"
    ],
    "esge": [
      "european society of gastrointestinal endoscopy"
    ],
    "and the european\nsociety of thoracic surgeons": [
      "ests"
    ],
    "ests": [
      "and the european\nsociety of thoracic surgeons",
      "and european society of thoracic surgeons",
      "and the european society of thoracic surgeons"
    ],
    "gv scagliotti": [
      "eds"
    ],
    "eds": [
      "gv scagliotti"
    ],
    "the thoracic surgery scoring\nsystem": [
      "thoracoscore"
    ],
    "thoracoscore": [
      "the thoracic surgery scoring\nsystem",
      "the thoracic surgery scoring system"
    ],
    "stereotactic body radiotherapy": [
      "sbrt"
    ],
    "respiratory oncology unit": [
      "pulmonology"
    ],
    "pulmonology": [
      "respiratory oncology",
      "respiratory oncology unit"
    ],
    "edegem": [
      "antwerp"
    ],
    "antwerp": [
      "edegem"
    ],
    "centre hospitalier universitaire\nvaudois": [
      "chuv"
    ],
    "early-stage nsclc": [
      "stages i ii"
    ],
    "stages i ii": [
      "early-stage nsclc"
    ],
    "locally advanced nsclc": [
      "stage iii"
    ],
    "stage iii": [
      "- locally advanced nsclc",
      "and unresectable locally advanced",
      "unresectable nsclc",
      "locally advanced nsclc",
      "treatment of locally advanced stage"
    ],
    "in paral\npractice guidelines": [
      "cpgs"
    ],
    "cpgs": [
      "in paral\npractice guidelines"
    ],
    "and a general consen\nconsensus process": [
      "see panel members listed in the appendix"
    ],
    "see panel members listed in the appendix": [
      "experts were involved in this\nconsensus process",
      "experts were involved in this consensus process",
      "and a general consen\nconsensus process"
    ],
    "experts were involved in this\nconsensus process": [
      "see panel members listed in the appendix"
    ],
    "controlled trials": [
      "rcts"
    ],
    "the\namerican college of chest physicians": [
      "accp"
    ],
    "as relative value depends on personal": [
      "usually unexplained or unquantifiable"
    ],
    "usually unexplained or unquantifiable": [
      "as relative value depends on personal"
    ],
    "respiratory literature": [
      "especially on exercise testing",
      "especially on exercise\ntesting"
    ],
    "especially on exercise\ntesting": [
      "respiratory literature"
    ],
    "use of the revised cardiac risk index": [
      "rcri"
    ],
    "rcri": [
      "use of the revised cardiac risk index"
    ],
    "and european society of thoracic surgeons": [
      "ests"
    ],
    "for sub-lobar resection": [
      "wide wedge resection or anatomical segmentectomy"
    ],
    "wide wedge resection or anatomical segmentectomy": [
      "for sub-lobar resection"
    ],
    "for which patients is limited": [
      "sub-lobar"
    ],
    "sub-lobar": [
      "special articles\n\n\n\nfor which patients is limited",
      "for which patients is limited"
    ],
    "especially those with ground-glass\nopacity": [
      "ggo"
    ],
    "ggo": [
      "especially those with ground-glass\nopacity",
      "especially those with ground-glass opacity"
    ],
    "special articles\n\n\n\nfor which patients is limited": [
      "sub-lobar"
    ],
    "other approaches such as local ablative": [
      "sabr"
    ],
    "sabr": [
      "consolidative stereotactic ablative radiotherapy",
      "other approaches such as local ablative",
      "solidative stereotactic ablative radiotherapy"
    ],
    "some trials": [
      "ialt"
    ],
    "ialt": [
      "some trials"
    ],
    "anatomical resection": [
      "lobectomy"
    ],
    "lobectomy": [
      "anatomical resection"
    ],
    "european society for\nmedical oncology": [
      "esmo"
    ],
    "boehringer ingelheim and astrazeneca": [
      "for lectures"
    ],
    "for lectures": [
      "boehringer ingelheim and astrazeneca"
    ],
    "results of\nthe initial": [
      "prevalence"
    ],
    "prevalence": [
      "results of\nthe initial",
      "results of the initial",
      "results of the\ninitial"
    ],
    "results of the\ninitial": [
      "prevalence"
    ],
    "results\nof the initial": [
      "prevalance"
    ],
    "prevalance": [
      "results\nof the initial",
      "results of the initial"
    ],
    "the thoracic surgery scoring system": [
      "thoracoscore"
    ],
    "robotic lobectomy for non-small cell lung cancer": [
      "nsclc"
    ],
    "fdg-pet and stereotactic body radiotherapy": [
      "sbrt"
    ],
    "respiratory oncology": [
      "pulmonology"
    ],
    "vrije\nuniversity medical centre": [
      "vumc"
    ],
    "vumc": [
      "university medical centre",
      "vrije university medical centre",
      "vrije\nuniversity medical centre"
    ],
    "university medical centre": [
      "vumc"
    ],
    "phase iii randomised clinical trial": [
      "rct"
    ],
    "platinum-based doublet chemotherapy": [
      "pbc"
    ],
    "pbc": [
      "five cycles of tremelimumab",
      "five cycles of\n\ntremelimumab",
      "platinum-based doublet chemotherapy"
    ],
    "carboplatin": [
      "arm a",
      "arm b"
    ],
    "arm a": [
      "carboplatin"
    ],
    "arm b": [
      "carboplatin"
    ],
    "pbc significantly improved pfs": [
      "primary\nendpoint",
      "primary endpoint"
    ],
    "primary\nendpoint": [
      "pbc significantly improved pfs"
    ],
    "pbc\nsignificantly improved pfs": [
      "primary endpoint"
    ],
    "primary endpoint": [
      "-year os",
      "pbc\nsignificantly improved pfs",
      "pbc significantly improved pfs",
      "level",
      "significantly improved os"
    ],
    "besides immune checkpoint\n\ninhibitor": [
      "ici"
    ],
    "ici": [
      "besides immune checkpoint inhibitor",
      "and have no prior immune checkpoint inhibitor",
      "besides immune checkpoint\n\ninhibitor"
    ],
    "esmo-magnitude of clinical benefit scale": [
      "mcbs",
      "esmo-mcbs"
    ],
    "mcbs": [
      "esmo-magnitude of clinical benefit scale"
    ],
    "five cycles of\n\ntremelimumab": [
      "pbc"
    ],
    "platinum-based chemo\ntherapy": [
      "cht"
    ],
    "food and drug administration": [
      "fda"
    ],
    "european medicines agency": [
      "ema"
    ],
    "of tumour cells": [
      "tcs"
    ],
    "tcs": [
      "of tumour cells"
    ],
    "level": [
      "primary endpoint"
    ],
    "tumour treating\nfields": [
      "ttfields"
    ],
    "ttfields": [
      "tumour treating fields",
      "tumour treating\nfields"
    ],
    "significantly improved os": [
      "primary endpoint"
    ],
    "ioanna ntai and claire bramley": [
      "esmo guidelines staff"
    ],
    "esmo guidelines staff": [
      "ioanna ntai and claire bramley",
      "jennifer\nlamarre and guy atchison",
      "jennifer lamarre and guy atchison",
      "valerie laforest"
    ],
    "valerie laforest": [
      "esmo\nguidelines staff",
      "esmo guidelines staff"
    ],
    "esmo\nguidelines staff": [
      "valerie laforest"
    ],
    "nicola latino and\nfrancesca chiovaro": [
      "esmo scientific affairs staff"
    ],
    "esmo scientific affairs staff": [
      "nicola\nlatino",
      "nicola latino and francesca chiovaro",
      "nicola latino",
      "nicola\nlatino and francesca chiovaro",
      "nicola latino and\nfrancesca chiovaro"
    ],
    "bristol\nmyers squibb": [
      "bms"
    ],
    "the european society for medical\noncology": [
      "esmo"
    ],
    "and the\neuropean thoracic oncology platform": [
      "foundation council\nmember"
    ],
    "foundation council\nmember": [
      "and the\neuropean thoracic oncology platform"
    ],
    "with a platinum-containing\nregimen": [
      "ipsos"
    ],
    "ipsos": [
      "with a platinum-containing\nregimen",
      "roche and                                regimen"
    ],
    "esmo clinical practice guideline": [
      "cpg"
    ],
    "cpg": [
      "esmo clinical practice guideline"
    ],
    "tyrosine kinase inhibitors": [
      "tkis"
    ],
    "tkis": [
      "tyrosine kinase inhibitors"
    ],
    "by next-generation sequencing": [
      "ngs"
    ],
    "ngs": [
      "multiplex platforms",
      "such as next-generation sequencing",
      "by next-generation sequencing"
    ],
    "egfr fish or immunohistochemistry": [
      "ihc"
    ],
    "positive anaplastic lymphoma kinase": [
      "alk"
    ],
    "or neurotrophic tyrosine\nreceptor kinase": [
      "ntrk"
    ],
    "ntrk": [
      "or neurotrophic tyrosine\nreceptor kinase",
      "or neurotrophic tyrosine receptor kinase",
      "- the neurotrophic receptor tyrosine kinase",
      "and the neurotrophic receptor tyrosine\nkinase"
    ],
    "detection is reliable by\nin situ hybridisation": [
      "ish"
    ],
    "ish": [
      "detection is reliable by\nin situ hybridisation",
      "detection is reliable by in situ hybridisation"
    ],
    "mesenchymal-epithelial transition": [
      "met"
    ],
    "met": [
      "mesenchymal-epithelial transition"
    ],
    "cell-free dna": [
      "cfdna"
    ],
    "cfdna": [
      "cell-free dna",
      "what is the role of liquid biopsy",
      "liquid biopsy"
    ],
    "multiplex platforms": [
      "ngs"
    ],
    "liquid biopsy": [
      "cfdna"
    ],
    "scan of\nthe chest and upper abdomen": [
      "including the liver and\nadrenal glands"
    ],
    "including the liver and\nadrenal glands": [
      "scan of\nthe chest and upper abdomen"
    ],
    "imaging of the central nervous system": [
      "cns"
    ],
    "cns": [
      "imaging of the central nervous system"
    ],
    "e\ndeoxy-d-glucose": [
      "fdg"
    ],
    "fdg": [
      "-deoxy-d-glucose",
      "e\ndeoxy-d-glucose"
    ],
    "union for international\ncancer control": [
      "uicc"
    ],
    "tumourenodeemetastasis": [
      "tnm",
      "staging and risk assessment\n\n\nthe tnm"
    ],
    "over platinum-based doublet\nchemotherapy": [
      "cht"
    ],
    "quality of life and progression-free survival": [
      "pfs"
    ],
    "phase iib\nrandomised controlled trial": [
      "rct"
    ],
    "demonstrating a superior\nmedian pfs": [
      "mpfs"
    ],
    "mpfs": [
      "demonstrating a superior\nmedian pfs",
      "demonstrating a superior median pfs"
    ],
    "and median os": [
      "mos"
    ],
    "mos": [
      "malaysian oncological society",
      "and median os",
      "malaysia",
      "the malaysian oncological society"
    ],
    "systemic progression\n\nlocal treatment": [
      "surgery or ft"
    ],
    "surgery or ft": [
      "systemic progression\n\nlocal treatment"
    ],
    "mpositive resistant disease": [
      "occurring in approximately half of\nthe patients"
    ],
    "occurring in approximately half of\nthe patients": [
      "mpositive resistant disease"
    ],
    "not european medicines agency": [
      "ema"
    ],
    "single-agent": [
      "third-generation"
    ],
    "third-generation": [
      "single-agent"
    ],
    "ensartinib": [
      "not ema approved",
      "not ema\napproved"
    ],
    "not ema\napproved": [
      "ensartinib"
    ],
    "j-alex": [
      "japan"
    ],
    "japan": [
      "jsmo",
      "j-alex"
    ],
    "and\nalesia": [
      "asia"
    ],
    "asia": [
      "and\nalesia",
      "and alesia"
    ],
    "and continue targeted": [
      "not mandatory for decision"
    ],
    "not mandatory for decision": [
      "and continue targeted"
    ],
    "interstitial lung disease": [
      "ild"
    ],
    "ild": [
      "interstitial lung disease"
    ],
    "not ema approved": [
      "ensartinib"
    ],
    "mainly altered lipid levels": [
      "aes"
    ],
    "alectinib was superior to single-agent cht": [
      "docetaxel or pemetrexed"
    ],
    "docetaxel or pemetrexed": [
      "alectinib was superior to single-agent cht"
    ],
    "entrectinib received food and\ndrug administration": [
      "fda"
    ],
    "the\nmedian duration of response": [
      "mdor"
    ],
    "mdor": [
      "the\nmedian duration of response",
      "the median duration of response"
    ],
    "tropomyosin receptor tyrosine kinase": [
      "trk"
    ],
    "trk": [
      "tropomyosin receptor tyrosine kinase"
    ],
    "disease progression\n\nlocal treatment": [
      "surgery or rt"
    ],
    "surgery or rt": [
      "local treatment",
      "disease progression\n\nlocal treatment",
      "oligoprogression\n\nlocal treatment",
      "- local treatment"
    ],
    "or combination therapy with a mek inhibitor": [
      "trametinib"
    ],
    "trametinib": [
      "or combination therapy with a mek inhibitor"
    ],
    "local treatment": [
      "surgery or rt"
    ],
    "a rearranged during transfection": [
      "ret"
    ],
    "ret": [
      "a rearranged during transfection"
    ],
    "trastuzumab deruxtecan": [
      "fda\napproved"
    ],
    "fda\napproved": [
      "trastuzumab deruxtecan"
    ],
    "the\nkirsten rat sarcoma virus": [
      "kras"
    ],
    "kras": [
      "the\nkirsten rat sarcoma virus",
      "the kirsten rat sarcoma virus"
    ],
    "data regarding the role of local ablative therapy": [
      "lat"
    ],
    "lat": [
      "data regarding the role of local ablative therapy"
    ],
    "one open-label phase iii rct": [
      "sindas"
    ],
    "sindas": [
      "one open-label phase iii rct"
    ],
    "in particular with the use\nof modern technologies": [
      "robotic systems"
    ],
    "robotic systems": [
      "in particular with the use\nof modern technologies",
      "in particular with the use of modern technologies"
    ],
    "esmo-magnitude of\nclinical benefit": [
      "esmo-mcbs"
    ],
    "may\nbenefit from lat": [
      "high-dose rt or surgery"
    ],
    "high-dose rt or surgery": [
      "may\nbenefit from lat",
      "from lat",
      "may benefit from lat"
    ],
    "jennifer\nlamarre and guy atchison": [
      "esmo guidelines staff"
    ],
    "nicola\nlatino": [
      "esmo scientific affairs staff"
    ],
    "and dr svetlana jezdic": [
      "esmo\nmedical affairs advisor",
      "esmo medical affairs advisor",
      "esmo medical affairs staff"
    ],
    "esmo\nmedical affairs advisor": [
      "and dr svetlana jezdic"
    ],
    "bristol-myers\nsquibb": [
      "bms"
    ],
    "asian\nthoracic oncology research group": [
      "atorg"
    ],
    "atorg": [
      "asian\nthoracic oncology research group",
      "asian thoracic oncology research group"
    ],
    "chinese lung\ncancer research foundation limited": [
      "clcrf"
    ],
    "clcrf": [
      "chinese lung\ncancer research foundation limited",
      "chinese lung cancer research foundation limited"
    ],
    "chinese society of clinical oncology": [
      "csco"
    ],
    "csco": [
      "chinese society of clinical oncology"
    ],
    "hong kong cancer fund": [
      "hkcf"
    ],
    "hkcf": [
      "hong kong cancer fund"
    ],
    "hong kong cancer therapy society": [
      "hkcts"
    ],
    "hkcts": [
      "hong kong cancer therapy society"
    ],
    "prep school": [
      "hong kong"
    ],
    "hong kong": [
      "prep school"
    ],
    "s education resource": [
      "per"
    ],
    "per": [
      "s education resource"
    ],
    "partnerships in international medical education": [
      "prime"
    ],
    "prime": [
      "partnerships in international medical education"
    ],
    "llc": [
      "rmei"
    ],
    "rmei": [
      "llc"
    ],
    "research\nto practice": [
      "rtp"
    ],
    "rtp": [
      "research\nto practice",
      "research to practice"
    ],
    "research": [
      "ukcccr",
      "sakk"
    ],
    "sakk": [
      "research"
    ],
    "international breast cancer study group": [
      "ibcsg"
    ],
    "ibcsg": [
      "international breast cancer study group"
    ],
    "s\nde clinique": [
      "asmac"
    ],
    "asmac": [
      "s\nde clinique",
      "s de clinique"
    ],
    "rzte": [
      "vsao"
    ],
    "vsao": [
      "rzte"
    ],
    "decins suisses": [
      "fmh"
    ],
    "fmh": [
      "decins suisses"
    ],
    "cancers": [
      "basel"
    ],
    "basel": [
      "cancers"
    ],
    "relay": [
      "cancer",
      "advanced non-small-cell lung cancer"
    ],
    "non-small-cell lung cancer": [
      "alesia",
      "nsclc"
    ],
    "alesia": [
      "non-small-cell lung cancer"
    ],
    "crizotinib-pretreated anaplastic lymphoma kinase": [
      "alk"
    ],
    "advanced non-small-cell lung cancer": [
      "relay",
      "nsclc"
    ],
    "fda prescribing information - rozlytrek": [
      "entrectinib"
    ],
    "entrectinib": [
      "fda prescribing information - rozlytrek"
    ],
    "retsevmo - summary of opinion": [
      "chmp"
    ],
    "chmp": [
      "products for human use",
      "tabrecta - summary of opinion",
      "retsevmo - summary of opinion"
    ],
    "tabrecta - summary of opinion": [
      "chmp"
    ],
    "prescribing information - rybrevant": [
      "amivantamab-vmjw"
    ],
    "amivantamab-vmjw": [
      "prescribing information - rybrevant"
    ],
    "solidative stereotactic ablative radiotherapy": [
      "sabr"
    ],
    "the european society for medical oncology": [
      "esmo"
    ],
    "to produce the pan-asian adapted": [
      "paga"
    ],
    "paga": [
      "to produce the pan-asian adapted"
    ],
    "indonesia": [
      "ishmo"
    ],
    "ishmo": [
      "indonesia"
    ],
    "india": [
      "ismpo"
    ],
    "ismpo": [
      "india"
    ],
    "jsmo": [
      "the japanese society of medical oncology",
      "japan",
      "the\njapanese society of medical oncology"
    ],
    "korea": [
      "ksmo"
    ],
    "ksmo": [
      "korea"
    ],
    "malaysia": [
      "mos"
    ],
    "the philippines": [
      "psmo"
    ],
    "psmo": [
      "the philippine society of\nmedical oncology",
      "and philippine society of medical\noncology",
      "and philippine society of medical oncology",
      "the philippines",
      "the philippine society of medical oncology"
    ],
    "singapore": [
      "sso"
    ],
    "sso": [
      "the singapore society of\noncology",
      "singapore",
      "the singapore society of oncology"
    ],
    "taiwan": [
      "tos"
    ],
    "tos": [
      "taiwan",
      "the taiwan oncology society"
    ],
    "and thailand": [
      "tsco"
    ],
    "tsco": [
      "and the\nthai society of clinical oncology",
      "and the thai society of clinical oncology",
      "and thailand"
    ],
    "and the neurotrophic receptor tyrosine\nkinase": [
      "ntrk"
    ],
    "esmo open\n\n\n\nrecommendation": [
      "gor"
    ],
    "gor": [
      "esmo open\n\n\n\nrecommendation"
    ],
    "esmomagnitude of clinical benefit scale": [
      "esmo-mcbs"
    ],
    "the\njapanese society of medical oncology": [
      "jsmo"
    ],
    "the malaysian oncological society": [
      "mos"
    ],
    "the philippine society of\nmedical oncology": [
      "psmo"
    ],
    "the singapore society of\noncology": [
      "sso"
    ],
    "the taiwan oncology society": [
      "tos"
    ],
    "and the\nthai society of clinical oncology": [
      "tsco"
    ],
    "only two of the six\nexpert members from the ksmo": [
      "tmk and hrk"
    ],
    "tmk and hrk": [
      "only two of the six\nexpert members from the ksmo",
      "only two of the six expert members from the ksmo"
    ],
    "performance status": [
      "ecog ps"
    ],
    "ecog ps": [
      "performance status"
    ],
    "scan of the chest and upper abdomen": [
      "including the liver and adrenal glands"
    ],
    "including the liver and adrenal glands": [
      "scan of the chest and upper abdomen"
    ],
    "resonance imaging": [
      "mri"
    ],
    "mri": [
      "and\na magnetic resonance imaging",
      "resonance imaging"
    ],
    "-positron emission topography": [
      "pet"
    ],
    "pet": [
      "-positron emission topography",
      "had undergone positron emission tomography",
      "of whom had undergone positron\nemission tomography"
    ],
    "union for international cancer control": [
      "uicc"
    ],
    "third-generation egfr tkis": [
      "such as osimertinib"
    ],
    "such as osimertinib": [
      "generation tki",
      "third-generation egfr tkis"
    ],
    "generation tki": [
      "such as osimertinib"
    ],
    "from lat": [
      "high-dose rt or surgery"
    ],
    "such as next-generation sequencing": [
      "ngs"
    ],
    "serious adverse events": [
      "saes"
    ],
    "saes": [
      "serious adverse events"
    ],
    "reported improved\nprogression-free survival": [
      "pfs"
    ],
    "which had an overall response rate": [
      "orr"
    ],
    "the median\nduration of response": [
      "dor"
    ],
    "esmo-magnitude of clinical benefit": [
      "esmo-mcbs"
    ],
    "esmo-magnitude of clinical\nbenefit": [
      "esmo-mcbs"
    ],
    "the addition of the chemotherapy": [
      "cht"
    ],
    "treatment-related aes": [
      "traes"
    ],
    "traes": [
      "what are the treatment-related adverse events",
      "treatment-related adverse events",
      "treatment-related aes"
    ],
    "and have no prior immune checkpoint inhibitor": [
      "ici"
    ],
    "the food and drug administration": [
      "fda"
    ],
    "s national medical products\nadministration": [
      "nsmpa"
    ],
    "nsmpa": [
      "s national medical products\nadministration"
    ],
    "ishmo\n\n\nthe jaminan kesehatan nasional": [
      "jkn"
    ],
    "jkn": [
      "ishmo\n\nthe jaminan kesehatan nasional",
      "ishmo\n\n\nthe jaminan kesehatan nasional"
    ],
    "there is no regulation of partial coverage": [
      "co-payment"
    ],
    "co-payment": [
      "there is no regulation of partial coverage"
    ],
    "esmo open\n\n\n\nprogram": [
      "pap"
    ],
    "pap": [
      "esmo open\n\n\n\nprogram",
      "program"
    ],
    "mandatory national health insurance": [
      "nhi"
    ],
    "nhi": [
      "mandatory national health insurance"
    ],
    "this includes ngs panel tests": [
      "partially reimbursed"
    ],
    "partially reimbursed": [
      "this includes ngs panel tests"
    ],
    "social\nsecurity and government officer": [
      "csmbs"
    ],
    "csmbs": [
      "social\nsecurity and government officer",
      "social security and government officer"
    ],
    "alk inhibitors": [
      "ceritinib and brigatinib only"
    ],
    "ceritinib and brigatinib only": [
      "alk inhibitors"
    ],
    "and atezolizumab": [
      "in the second-line setting",
      "in the\nsecond-line setting"
    ],
    "in the\nsecond-line setting": [
      "and atezolizumab"
    ],
    "erlotinib and osimertinib": [
      "second-line with reimbursement through the csmbs",
      "second-line with reimbursement\nthrough the csmbs"
    ],
    "second-line with reimbursement\nthrough the csmbs": [
      "erlotinib and osimertinib"
    ],
    "and the alk inhibitors ceritinib and\nbrigatinib": [
      "first-line"
    ],
    "first-line": [
      "and the alk inhibitors ceritinib and brigatinib",
      "and the alk inhibitors ceritinib and\nbrigatinib"
    ],
    "german": [
      "merck"
    ],
    "thoracic oncology research\ngroup": [
      "torg"
    ],
    "torg": [
      "thoracic oncology research group",
      "thoracic oncology research\ngroup"
    ],
    "and west japan oncology group": [
      "wjog"
    ],
    "wjog": [
      "and west japan oncology group"
    ],
    "product samples": [
      "nonrenumerated",
      "non-renumerated"
    ],
    "nonrenumerated": [
      "product samples"
    ],
    "and philippine society of medical\noncology": [
      "psmo"
    ],
    "trial steering committee": [
      "tsc"
    ],
    "tsc": [
      "trial steering committee"
    ],
    "independent data monitoring committee": [
      "idmc"
    ],
    "idmc": [
      "independent data monitoring committee"
    ],
    "ireland oesophagogastric group": [
      "ukiog"
    ],
    "ukiog": [
      "ireland oesophagogastric group"
    ],
    "celgene": [
      "bms"
    ],
    "hellenic cooperative oncology group": [
      "hecog"
    ],
    "hecog": [
      "hellenic cooperative oncology group"
    ],
    "chin med j": [
      "engl"
    ],
    "engl": [
      "chin med j"
    ],
    "commun": [
      "lond"
    ],
    "lond": [
      "commun",
      "cancer commun"
    ],
    "mertinib": [
      "osi"
    ],
    "osi": [
      "osimertinib",
      "mertinib"
    ],
    "platinum-pemetrexed in egfr-mutated": [
      "egfrm"
    ],
    "egfrm": [
      "with stage ibeiiia egfr mutation positive",
      "platinum-pemetrexed in egfr-mutated",
      "with stage ib-iiia egfr mutation positive"
    ],
    "advanced non-small cell lung cancer": [
      "nsclc"
    ],
    "cancer commun": [
      "lond"
    ],
    "e-mutant metastatic nsclc": [
      "mnsclc"
    ],
    "mnsclc": [
      "stage iv metastatic non-small-cell lung cancer",
      "e-mutant metastatic nsclc"
    ],
    "binimetinib in patients": [
      "pts"
    ],
    "pts": [
      "p repotrectinib in patients",
      "mo encorafenib plus binimetinib in patients",
      "osimertinib as adjuvant therapy in patients",
      "therapy in patients",
      "patients",
      "mo encorafenib plus\n\nbinimetinib in patients",
      "binimetinib in patients",
      "versus docetaxel in patients"
    ],
    "mutant advanced non-small cell lung cancer": [
      "nsclc"
    ],
    "patients": [
      "pts"
    ],
    "with epidermal growth factor receptor": [
      "egfr"
    ],
    "egfr": [
      "with epidermal growth factor receptor"
    ],
    "treatment of early stages": [
      "stages i-iiia",
      "stages i and ii",
      "stages i-ii"
    ],
    "stages i-iiia": [
      "treatment of early stages"
    ],
    "stages i-ii": [
      "treatment of early stages"
    ],
    "and the european medicines\nagency": [
      "ema"
    ],
    "chemotherapy": [
      "- everolimus\n   - cht",
      "adaura",
      "cht"
    ],
    "the median\nwas not reached": [
      "ne-ne"
    ],
    "ne-ne": [
      "the median\nwas not reached",
      "the median was not reached"
    ],
    "neoadjuvant immune checkpoint inhibitors": [
      "icis"
    ],
    "leads to\nincreased dfs versus best supportive care": [
      "bsc"
    ],
    "the\nimmune strategy in the": [
      "neo"
    ],
    "or docetaxel or pemetrexed": [
      "only in adenocarcinoma tumours",
      "only in\nadenocarcinoma tumours"
    ],
    "only in\nadenocarcinoma tumours": [
      "or docetaxel or pemetrexed"
    ],
    "post-operative radiotherapy": [
      "port"
    ],
    "port": [
      "postoperative radiotherapy",
      "comparing post-operative conformal radiotherapy",
      "post-operative radiotherapy"
    ],
    "treatment of locally advanced stage": [
      "stage iii"
    ],
    "negative endoscopic staging": [
      "ebus or eus"
    ],
    "ebus or eus": [
      "negative endoscopic staging"
    ],
    "of whom had undergone positron\nemission tomography": [
      "pet"
    ],
    "systemic treatment algorithm for early-stage": [
      "stage ib-iiia"
    ],
    "stage ib-iiia": [
      "systemic treatment algorithm for early-stage"
    ],
    "and unresectable locally advanced": [
      "stage iii"
    ],
    "general categories or stratification": [
      "symptom"
    ],
    "symptom": [
      "general categories or stratification"
    ],
    "and the food and drug administration": [
      "fda"
    ],
    "unresectable nsclc": [
      "stage iii"
    ],
    "concurrent chemoradiation therapy": [
      "pacific"
    ],
    "pacific": [
      "unresectable non-small-cell lung cancer",
      "concurrent chemoradiation therapy",
      "small-cell lung cancer"
    ],
    "adaura": [
      "chemotherapy"
    ],
    "d approval was based on all patient data": [
      "including stage ib"
    ],
    "including stage ib": [
      "d approval was based on all patient data",
      "approval was based on all patient data"
    ],
    "on tumour cells": [
      "as per the\nema-approved indication",
      "as per the ema-approved indication"
    ],
    "as per the\nema-approved indication": [
      "on tumour cells"
    ],
    "gico clara campal": [
      "hm-ciocc"
    ],
    "hm-ciocc": [
      "gico clara campal"
    ],
    "rolf stahel": [
      "esmo guidelines steering committee"
    ],
    "esmo guidelines steering committee": [
      "rolf stahel"
    ],
    "george pentheroudakis": [
      "chief medical officer of esmo"
    ],
    "chief medical officer of esmo": [
      "george pentheroudakis"
    ],
    "richard lutz and jennifer lamarre": [
      "esmo staff"
    ],
    "esmo staff": [
      "richard lutz and jennifer lamarre"
    ],
    "nicola latino": [
      "esmo scientific affairs staff"
    ],
    "research support as": [
      "sub"
    ],
    "with stage ibeiiia egfr mutation positive": [
      "egfrm"
    ],
    "nivolumab": [
      "nivo",
      "bristol myers squibb statement on opdivo"
    ],
    "nivo": [
      "nivolumab"
    ],
    "platinum-doublet\nchemotherapy": [
      "chemo"
    ],
    "chemo": [
      "platinum-doublet chemotherapy",
      "platinum-doublet\nchemotherapy",
      "platinum-based chemotherapy"
    ],
    "for\nresectable": [
      "ib-iiia"
    ],
    "ib-iiia": [
      "for resectable",
      "for\nresectable"
    ],
    "lung cancer": [
      "nsclc"
    ],
    "iii non-small-cell lung cancer": [
      "nsclc"
    ],
    "products for human use": [
      "chmp"
    ],
    "of circulating tumor dna": [
      "ctdna"
    ],
    "ctdna": [
      "of circulating tumor dna"
    ],
    "diques august pi i sunyer": [
      "idibaps"
    ],
    "idibaps": [
      "diques august pi i sunyer"
    ],
    "department of radiation oncology": [
      "maastro clinic",
      "maastro"
    ],
    "maastro clinic": [
      "department of radiation oncology"
    ],
    "and tumour mutational\nburden": [
      "tmb"
    ],
    "tmb": [
      "and tumour mutational\nburden"
    ],
    "staging and risk assessment\n\n\nthe tnm": [
      "tumourenodeemetastasis"
    ],
    "-deoxy-d-glucose positron\n\ne e\nemission tomography": [
      "fdg pet"
    ],
    "fdg pet": [
      "-deoxy-d-glucose positron\n\ne e\nemission tomography"
    ],
    "and\na magnetic resonance imaging": [
      "mri"
    ],
    "elevated lactate dehydrogenase": [
      "ldh"
    ],
    "ldh": [
      "elevated lactate dehydrogenase"
    ],
    "creatinine\nand lung function test": [
      "if localised disease"
    ],
    "if localised disease": [
      "creatinine\nand lung function test"
    ],
    "pet is available\nimaging of the brain": [
      "preferably mri"
    ],
    "preferably mri": [
      "pet is available\nimaging of the brain"
    ],
    "the use of granulocyte\ncolony-stimulating factor": [
      "g-csf"
    ],
    "g-csf": [
      "the use of granulocyte\ncolony-stimulating factor"
    ],
    "no\nimprovement in progression-free survival": [
      "pfs"
    ],
    "both given concurrently with cht": [
      "starting on cycle\ntwo"
    ],
    "starting on cycle\ntwo": [
      "both given concurrently with cht"
    ],
    "an historical southwest\n\noncology group": [
      "swog"
    ],
    "swog": [
      "an historical southwest\n\noncology group"
    ],
    "area under the curve": [
      "auc"
    ],
    "auc": [
      "area under the curve"
    ],
    "-year os": [
      "primary endpoint"
    ],
    "interval": [
      "tfi"
    ],
    "tfi": [
      "interval"
    ],
    "the\norr": [
      "primary outcome measure"
    ],
    "primary outcome measure": [
      "the\norr"
    ],
    "comparing\nnivolumab to topotecan": [
      "or amrubicin"
    ],
    "or amrubicin": [
      "comparing\nnivolumab to topotecan"
    ],
    "as second-line\ntreatment in unselected": [
      "platinum-sensitive and -resistant"
    ],
    "platinum-sensitive and -resistant": [
      "as second-line\ntreatment in unselected"
    ],
    "e\nrovalpituzumab tesirine": [
      "rova-t"
    ],
    "rova-t": [
      "e\nrovalpituzumab tesirine"
    ],
    "the preferred cht for patients with limited-stage": [
      "stage\ni-iii"
    ],
    "stage\ni-iii": [
      "the preferred cht for patients with limited-stage"
    ],
    "another reason for regular": [
      "long-term"
    ],
    "long-term": [
      "another reason for regular"
    ],
    "forthcoming": [
      "seventh"
    ],
    "seventh": [
      "forthcoming"
    ],
    "techniques": [
      "ct versus mri"
    ],
    "ct versus mri": [
      "techniques"
    ],
    "front med": [
      "lausanne"
    ],
    "lausanne": [
      "front med"
    ],
    "cell lung cancer": [
      "convert"
    ],
    "convert": [
      "cell lung cancer"
    ],
    "dose prophylactic cranial irradiation": [
      "pci"
    ],
    "extensive-stage small-cell lung cancer": [
      "caspian"
    ],
    "caspian": [
      "extensive-stage small-cell lung cancer",
      "cer"
    ],
    "cer": [
      "caspian"
    ],
    "plus ipilimumab": [
      "ipi"
    ],
    "ipi": [
      "plus ipilimumab"
    ],
    "or placebo": [
      "pbo"
    ],
    "pbo": [
      "or placebo"
    ],
    "therapy in patients": [
      "pts"
    ],
    "platinum-based chemotherapy": [
      "chemo",
      "cht"
    ],
    "bristol myers squibb statement on opdivo": [
      "nivolumab"
    ],
    "ukcccr": [
      "research"
    ],
    "and treatment of cancer": [
      "eortc"
    ],
    "eortc": [
      "and treatment of cancer"
    ],
    "randomized trial radiation therapy oncology group": [
      "rtog"
    ],
    "rtog": [
      "randomized trial radiation therapy oncology group"
    ],
    "a phase iii randomised clinical trial": [
      "rct"
    ],
    "tyrosine kinase inhibitor": [
      "tki"
    ],
    "oligoprogression\n\nlocal treatment": [
      "surgery or rt"
    ],
    "vascular endothelial growth factor": [
      "receptor"
    ],
    "receptor": [
      "vascular endothelial growth factor"
    ],
    "or food and drug administration": [
      "fda"
    ],
    "nicola\nlatino and francesca chiovaro": [
      "esmo scientific affairs staff"
    ],
    "esmo medical affairs staff": [
      "and dr svetlana jezdic"
    ],
    "the study of lung cancer": [
      "iaslc"
    ],
    "iaslc": [
      "the study of lung cancer"
    ],
    "global breast cancer initiative": [
      "gbci"
    ],
    "gbci": [
      "global breast cancer initiative"
    ],
    "european school of oncology": [
      "eso"
    ],
    "eso": [
      "european school of oncology"
    ],
    "and society for immunotherapy and cancer": [
      "sitc"
    ],
    "sitc": [
      "and society for immunotherapy and cancer"
    ],
    "p repotrectinib in patients": [
      "pts"
    ],
    "mo encorafenib plus\n\nbinimetinib in patients": [
      "pts"
    ],
    "versus docetaxel in patients": [
      "pts"
    ],
    "of molecular targets": [
      "escat"
    ],
    "escat": [
      "of molecular targets"
    ],
    "european society for medical oncology": [
      "esmo"
    ],
    "nice": [
      "nhs",
      "national institute for health and care excellence"
    ],
    "national institute for health and care excellence": [
      "nice"
    ],
    "world health organization": [
      "who"
    ],
    "australian national lung cancer screening program": [
      "nlcsp"
    ],
    "nlcsp": [
      "australian national lung cancer screening program"
    ],
    "- esmo": [
      "selected guidelines"
    ],
    "selected guidelines": [
      "- esmo"
    ],
    "- asco": [
      "stage iv guidelines"
    ],
    "stage iv guidelines": [
      "- asco"
    ],
    "low-dose ct": [
      "ldct"
    ],
    "nhs": [
      "nice"
    ],
    "vs insurance-based": [
      "nccn"
    ],
    "vs universal": [
      "who"
    ],
    "early": [
      "i-ii"
    ],
    "i-ii": [
      "early"
    ],
    "locally advanced": [
      "iii"
    ],
    "iii": [
      "locally advanced"
    ],
    "global": [
      "who"
    ],
    "- regular imaging": [
      "ct scans"
    ],
    "ct scans": [
      "- regular imaging"
    ],
    "- surgery": [
      "early stages"
    ],
    "early stages": [
      "- surgery"
    ],
    "- radiotherapy": [
      "radiation"
    ],
    "radiation": [
      "- radiotherapy"
    ],
    "global statistics": [
      "who"
    ],
    "using the guidelines into decision support": [
      "glides"
    ],
    "for all the newly european medicines agency": [
      "ema"
    ],
    "such as adjuvant chemotherapy": [
      "evaluates treatments with curative intent"
    ],
    "from different institutions": [
      "panel members"
    ],
    "and the early study interruption": [
      "even if based on pre-specified interim analysis"
    ],
    "even if based on pre-specified interim analysis": [
      "and the early study interruption"
    ],
    "-positive non-small-cell lung cancer": [
      "magrit"
    ],
    "early-stage and locally advanced": [
      "non-metastatic"
    ],
    "the primary end point was disease-free survival": [
      "dfs"
    ],
    "or best supportive care": [
      "bsc"
    ],
    "of patients with stage i to iii sclc": [
      "limited stage"
    ],
    "the college of american pathologists": [
      "cap"
    ],
    "association for molecular pathology": [
      "amp"
    ],
    "newly diagnosed nonepithelioid mesothelioma": [
      "biphasic or sarcomatoid"
    ],
    "biphasic or sarcomatoid": [
      "newly diagnosed nonepithelioid mesothelioma"
    ],
    "crispr therapeutics": [
      "inst"
    ],
    "pemetrexed": [
      "non squamous only"
    ],
    "non squamous only": [
      "pemetrexed"
    ],
    "all other patients": [
      "without egfr mutations"
    ],
    "without egfr mutations": [
      "all other patients"
    ],
    "treatment is now an egfr-targeted drug": [
      "osimertinib"
    ],
    "s note\n\nthis american society of clinical oncology": [
      "asco"
    ],
    "the median progression-free survival": [
      "pfs"
    ],
    "and vascular endothelial growth factor": [
      "vegf"
    ],
    "though rates of immune-related aes": [
      "iraes"
    ],
    "black diamond therapeutics": [
      "inst"
    ],
    "in the absence of contraindications to bevacizumab": [
      "nab-paclitaxel with or without bevacizumab"
    ],
    "squamous cell carcinoma": [
      "scc"
    ],
    "scc": [
      "squamous cell carcinoma"
    ],
    "asco practice guideline staff": [
      "health research methods"
    ],
    "tumor proportion score": [
      "tps"
    ],
    "tps": [
      "tumor proportion score"
    ],
    "rate": [
      "orr"
    ],
    "with a median duration of response": [
      "dor"
    ],
    "journal of clinical oncology": [
      "asco"
    ],
    "dizal pharma": [
      "inst"
    ],
    "weak": [
      "continued on following page"
    ],
    "continued on following page": [
      "weak"
    ],
    "asco practice guidelines staff": [
      "health research methods"
    ],
    "infusion-related reactions": [
      "composite term"
    ],
    "composite term": [
      "infusion-related reactions"
    ],
    "limited-stage sclc": [
      "ls-sclc"
    ],
    "ls-sclc": [
      "limited-stage sclc"
    ],
    "if ps improves\n- consolidation immunotherapy": [
      "durvalumab"
    ],
    "extensive-stage sclc": [
      "es-sclc"
    ],
    "es-sclc": [
      "extensive-stage sclc"
    ],
    "a bispecific t-cell engager": [
      "bite"
    ],
    "the most common ae was cytokine release syndrome": [
      "crs"
    ],
    "and progression-free survival": [
      "pfs"
    ],
    "progression-free survival": [
      "pfs"
    ],
    "all-cause": [
      "adverse events"
    ],
    "immune-related aes": [
      "any grade"
    ],
    "any grade": [
      "immune-related aes"
    ],
    "associated neurotoxicity syndrome": [
      "icans"
    ],
    "has grouped lung and thymic neuroendocrine tumours": [
      "nets"
    ],
    "and large cell neuroendocrine carcinoma": [
      "lcnec"
    ],
    "and thymic carcinoid": [
      "thc"
    ],
    "due to growth hormone-releasing hormone": [
      "ghrh"
    ],
    "surgery represents the treatment of choice for lcs": [
      "both tcs and acs"
    ],
    "both tcs and acs": [
      "surgery represents the treatment of choice for lcs"
    ],
    "with options discussed in these guidelines": [
      "or systemic therapies"
    ],
    "in case of clinical": [
      "functioning syndrome"
    ],
    "parathyroid hormone": [
      "pth"
    ],
    "palliative surgery or radiofrequency ablation": [
      "rfa"
    ],
    "peptide receptor radionuclide therapy": [
      "- prrt",
      "prrt"
    ],
    "what is the role of somatostatin analogues": [
      "ssas"
    ],
    "uorouracil": [
      "folfox"
    ],
    "in case of uncontrolled cs": [
      "as alternative second-line",
      "as a potential second-line"
    ],
    "beyond ssas and or everolimus": [
      "or mainly third-line alternative",
      "or mainly third-line therapy"
    ],
    "as a potential second-line": [
      "in case of uncontrolled cs"
    ],
    "if located in the anterior mediastinum": [
      "thymic net recurrences may be local"
    ],
    "intrathoracic especially pleural": [
      "regional"
    ],
    "an esmo magnitude of clinical benefit scale": [
      "esmo-mcbs"
    ],
    "results from the randomized phase iii study": [
      "sanet-ep"
    ],
    "sanet-ep": [
      "results from the randomized phase iii study"
    ],
    "- ssas": [
      "somatostatin analogues"
    ],
    "somatostatin analogues": [
      "- ssas"
    ],
    "- prrt": [
      "peptide receptor radionuclide therapy"
    ],
    "- everolimus\n   - cht": [
      "chemotherapy"
    ],
    "in patients with refractory cs": [
      "carcinoid syndrome"
    ],
    "carcinoid syndrome": [
      "in patients with refractory cs"
    ],
    "due to the lack of specific lc": [
      "lung carcinoid"
    ],
    "lung carcinoid": [
      "due to the lack of specific lc"
    ],
    "the flowchart is divided into sections for tc": [
      "typical carcinoid"
    ],
    "typical carcinoid": [
      "the flowchart is divided into sections for tc"
    ],
    "and thc": [
      "thymic carcinoid"
    ],
    "thymic carcinoid": [
      "and thc"
    ],
    "or endoscopic ultrasound": [
      "eus"
    ],
    "not otherwise specified": [
      "the rate of nos"
    ],
    "the union for international cancer control": [
      "uicc"
    ],
    "proposed that ais be classified as tis": [
      "ais"
    ],
    "and peripheral tumour": [
      "outer third of the lung"
    ],
    "outer third of the lung": [
      "and peripheral tumour"
    ],
    "current complaint of chest pain": [
      "myocardial ischaemia"
    ],
    "myocardial ischaemia": [
      "current complaint of chest pain"
    ],
    "stages i and ii": [
      "treatment of early stages"
    ],
    "including": [
      "cabg or pci"
    ],
    "undergo platinum-based cht": [
      "preferably cisplatin"
    ],
    "preferably cisplatin": [
      "undergo platinum-based cht"
    ],
    "phoma kinase": [
      "alk"
    ],
    "and the european society of thoracic surgeons": [
      "ests"
    ],
    "experts were involved in this consensus process": [
      "see panel members listed in the appendix"
    ],
    "- locally advanced nsclc": [
      "stage iii"
    ],
    "the american college of chest physicians": [
      "accp"
    ],
    "especially on exercise testing": [
      "respiratory literature"
    ],
    "especially those with ground-glass opacity": [
      "ggo"
    ],
    "results of the initial": [
      "prevalance",
      "prevalence"
    ],
    "video-assisted thoracic surgery": [
      "vats"
    ],
    "vrije university medical centre": [
      "vumc"
    ],
    "besides immune checkpoint inhibitor": [
      "ici"
    ],
    "five cycles of tremelimumab": [
      "pbc"
    ],
    "tumour treating fields": [
      "ttfields"
    ],
    "maastro": [
      "department of radiation oncology"
    ],
    "nicola latino and francesca chiovaro": [
      "esmo scientific affairs staff"
    ],
    "oncology group": [
      "chair of the steering committee"
    ],
    "chair of the steering committee": [
      "oncology group"
    ],
    "roche and                                regimen": [
      "ipsos"
    ],
    "sion on or after            platinum-based therapy": [
      "lunar"
    ],
    "lunar": [
      "sion on or after            platinum-based therapy"
    ],
    "fusions": [
      "rearrangements"
    ],
    "rearrangements": [
      "fusions"
    ],
    "or neurotrophic tyrosine receptor kinase": [
      "ntrk"
    ],
    "detection is reliable by in situ hybridisation": [
      "ish"
    ],
    "-deoxy-d-glucose": [
      "fdg"
    ],
    "tumour-node-metastasis": [
      "tnm"
    ],
    "over platinum-based doublet chemotherapy": [
      "cht"
    ],
    "phase iib randomised controlled trial": [
      "rct"
    ],
    "demonstrating a superior median pfs": [
      "mpfs"
    ],
    "m-positive resistant disease": [
      "occurring in approximately half of the patients"
    ],
    "occurring in approximately half of the patients": [
      "m-positive resistant disease"
    ],
    "and alesia": [
      "asia"
    ],
    "entrectinib received food and drug administration": [
      "fda"
    ],
    "the median duration of response": [
      "mdor",
      "dor"
    ],
    "deruxtecan": [
      "fda approved"
    ],
    "fda approved": [
      "deruxtecan"
    ],
    "the kirsten rat sarcoma virus": [
      "kras"
    ],
    "in particular with the use of modern technologies": [
      "robotic systems"
    ],
    "may benefit from lat": [
      "high-dose rt or surgery"
    ],
    "jennifer lamarre and guy atchison": [
      "esmo guidelines staff"
    ],
    "esmo medical affairs advisor": [
      "and dr svetlana jezdic"
    ],
    "asian thoracic oncology research group": [
      "atorg"
    ],
    "chinese lung cancer research foundation limited": [
      "clcrf"
    ],
    "research to practice": [
      "rtp"
    ],
    "s de clinique": [
      "asmac"
    ],
    "-rearranged advanced non-small-cell lung cancer": [
      "nsclc"
    ],
    "consolidative stereotactic ablative radiotherapy": [
      "sabr"
    ],
    "- the neurotrophic receptor tyrosine kinase": [
      "ntrk"
    ],
    "the japanese society of medical oncology": [
      "jsmo"
    ],
    "the philippine society of medical oncology": [
      "psmo"
    ],
    "the singapore society of oncology": [
      "sso"
    ],
    "and the thai society of clinical oncology": [
      "tsco"
    ],
    "only two of the six expert members from the ksmo": [
      "tmk and hrk"
    ],
    "what is the role of liquid biopsy": [
      "cfdna"
    ],
    "reported improved progression-free survival": [
      "pfs"
    ],
    "stage iv metastatic non-small-cell lung cancer": [
      "mnsclc"
    ],
    "egfr mutation": [
      "classical activating mutations"
    ],
    "classical activating mutations": [
      "egfr mutation"
    ],
    "- local treatment": [
      "surgery or rt"
    ],
    "- objective response rate": [
      "orr"
    ],
    "- duration of response": [
      "dor"
    ],
    "treatment-related adverse events": [
      "traes"
    ],
    "what are the treatment-related adverse events": [
      "traes"
    ],
    "ishmo\n\nthe jaminan kesehatan nasional": [
      "jkn"
    ],
    "program": [
      "pap"
    ],
    "social security and government officer": [
      "csmbs"
    ],
    "in the second-line setting": [
      "and atezolizumab"
    ],
    "second-line with reimbursement through the csmbs": [
      "erlotinib and osimertinib"
    ],
    "and the alk inhibitors ceritinib and brigatinib": [
      "first-line"
    ],
    "tmk": [
      "author"
    ],
    "author": [
      "msi",
      "sak",
      "hrk",
      "ddwl",
      "tmk",
      "cew",
      "jchy"
    ],
    "hrk": [
      "author"
    ],
    "sak": [
      "author"
    ],
    "thoracic oncology research group": [
      "torg"
    ],
    "ddwl": [
      "author"
    ],
    "msi": [
      "author"
    ],
    "jchy": [
      "author"
    ],
    "cew": [
      "author"
    ],
    "non-renumerated": [
      "product samples"
    ],
    "and philippine society of medical oncology": [
      "psmo"
    ],
    "malaysian oncological society": [
      "mos"
    ],
    "medical guideline document - esmo open references": [
      "continued"
    ],
    "mo encorafenib plus binimetinib in patients": [
      "pts"
    ],
    "e-mutant advanced non-small cell lung cancer": [
      "nsclc"
    ],
    "and the european medicines agency": [
      "ema"
    ],
    "with or without prior adjuvant chemotherapy": [
      "cht"
    ],
    "the median was not reached": [
      "ne-ne"
    ],
    "leads to increased dfs versus best supportive care": [
      "bsc"
    ],
    "expression": [
      "for unresectable nsclc",
      "for completely resected nsclc"
    ],
    "for unresectable nsclc": [
      "expression"
    ],
    "for completely resected nsclc": [
      "expression"
    ],
    "only in adenocarcinoma tumours": [
      "or docetaxel or pemetrexed"
    ],
    "the immune strategy in the": [
      "neo"
    ],
    "resection and after": [
      "neo"
    ],
    "postoperative radiotherapy": [
      "port"
    ],
    "had undergone positron emission tomography": [
      "pet"
    ],
    "disease-free survival": [
      "dfs"
    ],
    "- chemotherapy and radiotherapy": [
      "cht and rt"
    ],
    "cht and rt": [
      "- chemotherapy and radiotherapy"
    ],
    "control": [
      "median"
    ],
    "median": [
      "control"
    ],
    "approval was based on all patient data": [
      "including stage ib"
    ],
    "as per the ema-approved indication": [
      "on tumour cells"
    ],
    "osimertinib as adjuvant therapy in patients": [
      "pts"
    ],
    "with stage ib-iiia egfr mutation positive": [
      "egfrm"
    ],
    "platinum-doublet chemotherapy": [
      "chemo"
    ],
    "for resectable": [
      "ib-iiia"
    ],
    "comparing post-operative conformal radiotherapy": [
      "port"
    ],
    "unresectable non-small-cell lung cancer": [
      "pacific"
    ]
  },
  "abbreviations": {
    "esmo": [
      "european society for medical oncology",
      "living guideline\n\nthe following european society for medical oncology",
      "european society of medical oncology",
      "the following european society for medical oncology",
      "european\nsociety of medical oncology",
      "european society for medical\noncology",
      "the most recent european society for medical oncology",
      "the european society for medical oncology",
      "european society for\nmedical oncology"
    ],
    "asco": [
      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc",
      "american society of clinical\noncology",
      "american society of clinical oncology",
      "american\nsociety of clinical oncology",
      "american society of clinical\n\noncology",
      "this american society of clinical oncology",
      "journal of clinical oncology"
    ],
    "aiom": [
      "the italian association of medical oncology",
      "italian association\nof medical oncology",
      "italian association of medical oncology"
    ],
    "nccn": [
      "american cancer centers",
      "national comprehensive cancer network"
    ],
    "glides": [
      "guidelines into decision support",
      "guidelines into decision\nsupport",
      "ecision support"
    ],
    "glc": [
      "guidelines committee"
    ],
    "mcbs": [
      "magnitude of clinical benefit score",
      "magnitude of clinical benefit scale",
      "magnitude\nof clinical benefit score"
    ],
    "ema": [
      "european medicines\nagency",
      "european medicines agency"
    ],
    "sclc": [
      "what are the recommended treatment options for patients with relapsed small cell lung cancer",
      "clinical practice guidelines on small cell lung\ncancer",
      "clinical practice guidelines on small cell lung cancer",
      "what is the treatment algorithm for patients with small cell lung cancer",
      "small cell lung cancer"
    ],
    "cco": [
      "cancer care ontario"
    ],
    "astro": [
      "executive summary of an american society for\nradiation oncology",
      "executive summary of an american society for radiation oncology"
    ],
    "inst": [
      "pharmaceuticals",
      "exelixis",
      "astex pharmaceuticals",
      "boehringer ingelheim",
      "regeneron",
      "myers squibb",
      "cullinan oncology",
      "guardant health",
      "arcus biosciences",
      "palobiofarma",
      "sutro biopharma",
      "merck serono",
      "verastem",
      "genomics",
      "elevation oncology",
      "bristol myers squibb foundation",
      "calithera biosciences",
      "takeda",
      "black diamond therapeutics",
      "novartis",
      "bristol myers squibb",
      "bayer",
      "constellation pharmaceuticals",
      "jazz pharmaceuticals",
      "therapeutics",
      "blueprint medicines",
      "roche",
      "turning point therapeutics",
      "janssen oncology",
      "lilly",
      "kline canada",
      "black diamond\ntherapeutics",
      "zeneca",
      "astra zeneca",
      "harpoon therapeutics",
      "inhibrx",
      "kline",
      "pfizer",
      "revolution medicines",
      "advaxis",
      "dizal pharma",
      "heart therapeutics",
      "merck",
      "janssen",
      "macrogenics",
      "summit therapeutics",
      "genentech",
      "bristol myers\nsquibb",
      "amgen",
      "puma biotechnology",
      "vivace therapeutics",
      "zeneca canada",
      "nuvation bio",
      "immune",
      "forward",
      "polaris",
      "dizal\npharma",
      "trizell",
      "mirati therapeutics",
      "dohme"
    ],
    "ct": [
      "computed tomography",
      "clinicians should use a diagnostic chest computed tomography",
      "the use of computed tomography",
      "the use of\ncomputed tomography"
    ],
    "mri": [
      "what is the role of brain magnetic resonance imaging"
    ],
    "sbrt": [
      "stereotactic body radiotherapy",
      "salvage stereotactic body radiation therapy"
    ],
    "cap": [
      "pathologists",
      "college of american pathologists"
    ],
    "iaslc": [
      "study of lung cancer",
      "pathology committee chair\nfor international association for the study of lung cancer",
      "international association for\nthe study of lung cancer",
      "international association for the study of lung cancer",
      "international association for the\nstudy of lung cancer",
      "international association for the\n\nstudy of lung cancer",
      "the international association for the study of lung cancer",
      "the\ninternational association for the study of lung cancer",
      "pathology committee chair for international association for the study of lung cancer"
    ],
    "amp": [
      "association for molecular pathology",
      "association\nfor molecular pathology"
    ],
    "ihc": [
      "immunohistochemistry"
    ],
    "ctc": [
      "there is currently insufficient evidence to support the use of circulating tumor cell"
    ],
    "mars": [
      "although the results from the mesothelioma and radical surgery"
    ],
    "os": [
      "the median overall survival",
      "the only data published thus far pertain to the dual primary end points of overall survival",
      "median overall survival",
      "the median\noverall survival",
      "overall survival"
    ],
    "elsevier": [
      "clinical lung cancer"
    ],
    "rct": [
      "one randomized controlled trial"
    ],
    "ps": [
      "eastern cooperative oncology group performance status",
      "eastern cooperative oncology group performance\nstatus"
    ],
    "orr": [
      "objective response rate",
      "reuss et al\n\n\n\nrate",
      "is result in a lower overall response rate",
      "is result in a lower overall response\nrate"
    ],
    "pci": [
      "what is the role of prophylactic cranial irradiation",
      "prophylactic cranial irradiation"
    ],
    "fda": [
      "osimertinib is approved by both the united states food and drug administration",
      "osimertinib is approved by both the united states food and\ndrug administration",
      "united states food and drug administration",
      "food and drug administration",
      "these results led to the food\n\nand drug administration",
      "entrectinib received food and drug administration",
      "entrectinib received food and\ndrug administration"
    ],
    "crs": [
      "cytokine release syndrome"
    ],
    "ikv": [
      "department of surgical sciences"
    ],
    "who": [
      "the latest world health organization",
      "world health organization",
      "the recent world health organization",
      "global",
      "global statistics"
    ],
    "lc": [
      "these guidelines are restricted to lung carcinoid",
      "these\nguidelines are restricted to lung carcinoid"
    ],
    "seer": [
      "end results",
      "epidemiology and end results"
    ],
    "uicc": [
      "union for international cancer control",
      "union for international\ncancer control",
      "edition of the union for international cancer control",
      "edition of the union for\ninternational cancer control",
      "union for\ninternational cancer control"
    ],
    "gep": [
      "based on\napproval and recommendations in gastroenteropancreatic",
      "based on approval and recommendations in gastroenteropancreatic"
    ],
    "pth": [
      "annals of oncology\n\n\n\nparathyroid hormone"
    ],
    "rfa": [
      "palliative surgery or radiofrequency ablation",
      "palliative surgery\nor radiofrequency ablation",
      "for these patients radiofrequency ablation"
    ],
    "recist": [
      "cs with response evaluation criteria in solid tumours",
      "cs with response evaluation criteria\nin solid tumours",
      "measurements and response assessment should follow response evaluation criteria in solid tumours",
      "measurements and response assessment should follow\nresponse evaluation criteria in solid tumours"
    ],
    "gemox": [
      "oxaliplatin combined with gemcitabine"
    ],
    "lan": [
      "lanreotide autogel"
    ],
    "chuv": [
      "centre hospitalier universitaire\nvaudois",
      "centre hospitalier universitaire vaudois"
    ],
    "nlst": [
      "national cancer institute\nannounced the results of the national lung cancer screening\ntrial",
      "national cancer institute announced the results of the national lung cancer screening trial",
      "the much larger national lung cancer screening trial"
    ],
    "bts": [
      "guidelines developed by the british thoracic society"
    ],
    "pet": [
      "the latter recommend a lesser reliance on positron emission tomography"
    ],
    "nice": [
      "national institute for health and care excellence",
      "national institute for health and care\nexcellence"
    ],
    "accp": [
      "american college of chest physicians"
    ],
    "rcri": [
      "evaluation of the cardiac risk assessment for lung resections by the recalibrated thoracic revised cardiac risk index",
      "evaluation of the cardiac risk assessment for lung resections\nby the recalibrated thoracic revised cardiac risk index"
    ],
    "lcsg": [
      "based on the lung cancer study group"
    ],
    "egfr": [
      "for cases with mutation in epidermal growth factor receptor"
    ],
    "rtog": [
      "radiation therapy oncology group",
      "data from a completed prospective\nradiation therapy oncology group",
      "data from a completed prospective radiation therapy oncology group"
    ],
    "esge": [
      "european society of gastrointestinal endoscopy"
    ],
    "ers": [
      "european respiratory society"
    ],
    "ests": [
      "european association of thoracic surgeons",
      "european\nsociety of thoracic surgeons",
      "european society of thoracic surgeons"
    ],
    "thoracoscore": [
      "the thoracic surgery scoring\nsystem",
      "the thoracic surgery scoring system"
    ],
    "pulmonology": [
      "respiratory oncology",
      "respiratory oncology unit"
    ],
    "acs": [
      "lung cancer screening guidelines published by the\namerican cancer society",
      "lung cancer screening guidelines published by the american cancer society"
    ],
    "ialt": [
      "some trials"
    ],
    "anita": [
      "adjuvant navelbine international trialist association"
    ],
    "sabr": [
      "what are the indications and recommendations for salvage surgery after stereotactic ablative radiotherapy",
      "consolidative stereotactic ablative radiotherapy",
      "radiographic changes after lung stereotactic ablative radiotherapy",
      "what are the outcomes comparing stereotactic ablative radiotherapy",
      "radiographic changes after lung stereotactic\nablative radiotherapy"
    ],
    "vumc": [
      "university medical centre",
      "vrije university medical centre",
      "vrije\nuniversity medical centre"
    ],
    "ub": [
      "bemeneed"
    ],
    "bms": [
      "myers squibb",
      "myers\nsquibb",
      "bristol\nmyers squibb",
      "bristol myers\nsquibb",
      "bristol myers squibb"
    ],
    "msd": [
      "dohme"
    ],
    "eortc": [
      "chair of the european organisation for research and treatment of cancer",
      "treatment of cancer",
      "chair of the european\norganisation for research and treatment of cancer",
      "european organisation for research and treatment of cancer",
      "european\norganisation for research and treatment of cancer"
    ],
    "cpg": [
      "clinical practice guideline"
    ],
    "escat": [
      "scale for clinical actionability of\nmolecular targets",
      "targets",
      "scale for clinical actionability of molecular targets"
    ],
    "alk": [
      "positive anaplastic lymphoma kinase"
    ],
    "ish": [
      "detection is reliable by\nin situ hybridisation",
      "detection is reliable by in situ hybridisation"
    ],
    "cns": [
      "imaging of the central nervous system"
    ],
    "ajcc": [
      "american joint committee on cancer",
      "american joint\ncommittee on cancer"
    ],
    "vb": [
      "ch cl"
    ],
    "ae": [
      "serious adverse event"
    ],
    "ild": [
      "interstitial lung disease"
    ],
    "kras": [
      "the\nkirsten rat sarcoma virus",
      "the kirsten rat sarcoma virus"
    ],
    "lat": [
      "data regarding the role of local ablative therapy"
    ],
    "eano": [
      "oncology"
    ],
    "gsk": [
      "kline"
    ],
    "nvalt": [
      "lung cancer group and past secretary and current\nchair of the nederlandse vereniging van artsen voor longziekten en tuberculose",
      "nederlandse vereniging van artsen voor longziekten en tuberculose"
    ],
    "atorg": [
      "asian\nthoracic oncology research group",
      "asian thoracic oncology research group"
    ],
    "clcrf": [
      "chinese lung\ncancer research foundation limited",
      "chinese lung cancer research foundation limited"
    ],
    "csco": [
      "china",
      "chinese society of clinical oncology",
      "chinese\nsociety of clinical oncology"
    ],
    "hkcf": [
      "hong kong cancer fund"
    ],
    "hkcts": [
      "hong kong cancer therapy society"
    ],
    "per": [
      "education resource"
    ],
    "prime": [
      "partnerships in international medical education"
    ],
    "rtp": [
      "research\nto practice",
      "research to practice"
    ],
    "samo": [
      "president of swiss\nacademy of multidisciplinary oncology",
      "president of swiss academy of multidisciplinary oncology"
    ],
    "sakk": [
      "president of lung group for swiss group for clinical cancer\nresearch",
      "president of lung group for swiss group for clinical cancer research",
      "research"
    ],
    "etop": [
      "european thoracic oncology platform"
    ],
    "ibcsg": [
      "international breast cancer study group"
    ],
    "aacr": [
      "partners member of american association of cancer research",
      "partners member\nof american association of cancer research"
    ],
    "asmac": [
      "clinique"
    ],
    "basel": [
      "cancers"
    ],
    "chmp": [
      "committee for medicinal products for human use",
      "summary of opinion",
      "products for human use"
    ],
    "paga": [
      "asian adapted"
    ],
    "ishmo": [
      "indonesian society\nof hematology and medical oncology",
      "indonesia",
      "indonesian society of hematology and medical oncology"
    ],
    "jsmo": [
      "japan",
      "japanese society of medical oncology"
    ],
    "ksmo": [
      "korean society for medical oncology",
      "korea"
    ],
    "mos": [
      "malaysian oncological society",
      "malaysia"
    ],
    "psmo": [
      "philippine society of medical oncology",
      "philippines",
      "philippine society of medical\noncology",
      "philippine society of\nmedical oncology"
    ],
    "sso": [
      "singapore",
      "singapore society of\noncology",
      "singapore society of oncology"
    ],
    "tos": [
      "taiwan",
      "taiwan oncology society"
    ],
    "tsco": [
      "thailand",
      "thai society of clinical oncology"
    ],
    "ismpo": [
      "indian society of medical and paediatric oncology",
      "indian\nsociety of medical and paediatric oncology"
    ],
    "nsmpa": [
      "national medical products\nadministration"
    ],
    "nmpa": [
      "chinese national\nmedical products administration",
      "chinese national medical products administration"
    ],
    "jkn": [
      "the jaminan kesehatan nasional"
    ],
    "fornas": [
      "national standard of medication list",
      "na\ntional drug formulary",
      "national standard of\nmedication list",
      "national drug formulary"
    ],
    "pap": [
      "open\n\n\n\nprogram"
    ],
    "pdma": [
      "it may take from several months to years for the pharmaceuticals and medical devices agency",
      "it may take\nfrom several months to years for the pharmaceuticals and\nmedical devices agency"
    ],
    "nhi": [
      "national health insurance"
    ],
    "torg": [
      "thoracic oncology research group",
      "thoracic oncology research\ngroup"
    ],
    "wjog": [
      "west japan oncology group"
    ],
    "tsc": [
      "trial steering committee"
    ],
    "idmc": [
      "committee",
      "independent data monitoring committee"
    ],
    "ukiog": [
      "ireland oesophagogastric group"
    ],
    "lond": [
      "commun",
      "cancer commun"
    ],
    "nivo": [
      "nivolumab"
    ],
    "pa": [
      "philadelphia"
    ],
    "idibaps": [
      "august pi i sunyer"
    ],
    "swog": [
      "an historical southwest\n\noncology group"
    ],
    "cr": [
      "patients with a complete response"
    ],
    "rova-t": [
      "rovalpituzumab tesirine"
    ],
    "lausanne": [
      "front med"
    ],
    "coordinating": [
      "united kingdom"
    ],
    "ukcccr": [
      "research"
    ],
    "icf": [
      "international cancer foundation"
    ],
    "gbci": [
      "global breast cancer initiative"
    ],
    "esco": [
      "college of the european school of oncology"
    ],
    "eso": [
      "european school of oncology"
    ],
    "sitc": [
      "society for immunotherapy and cancer"
    ],
    "actionability": [
      "scale for clinical"
    ],
    "disease": [
      "centers for"
    ],
    "nlcsp": [
      "australian national lung cancer screening program"
    ],
    "iii": [
      "locally advanced"
    ],
    "iv": [
      "advanced"
    ],
    "nsclc": [
      "small cell lung cancer",
      "cell lung cancer"
    ],
    "uk": [
      "guidelines"
    ],
    "scc": [
      "squamous cell carcinoma"
    ],
    "hr": [
      "hazard ratio"
    ],
    "pfs": [
      "free survival"
    ],
    "all-cause": [
      "adverse events"
    ],
    "tc": [
      "typical carcinoid"
    ],
    "ac": [
      "atypical carcinoid"
    ],
    "prrt": [
      "what is the role of peptide receptor radionuclide therapy"
    ],
    "dipnech": [
      "diffuse idiopathic pulmonary neuroendocrine cell hyperplasia"
    ],
    "port": [
      "postoperative radiotherapy",
      "what are the outcomes and recommendations for postoperative radiotherapy",
      "what is the current evidence and recommendation for postoperative radiotherapy",
      "radiotherapy"
    ],
    "i-v": [
      "classification system showing five levels of evidence"
    ],
    "vats": [
      "assisted thoracic surgery"
    ],
    "maastro": [
      "department of radiation oncology"
    ],
    "pi": [
      "institutional funding as local principal investigator"
    ],
    "ipsos": [
      "roche and                                regimen"
    ],
    "rt": [
      "the addition of radiotherapy"
    ],
    "ntrk": [
      "the neurotrophic receptor tyrosine kinase"
    ],
    "dor": [
      "duration of response"
    ],
    "continued": [
      "open references"
    ],
    "dfs": [
      "free survival"
    ]
  }
}